Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more
Shinpoong Pharmaceutical Co Ltd (019175) - Net Assets
Latest net assets as of September 2025: ₩264.20 Billion KRW
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has net assets worth ₩264.20 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩341.59 Billion) and total liabilities (₩77.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩264.20 Billion |
| % of Total Assets | 77.34% |
| Annual Growth Rate | 3.03% |
| 5-Year Change | -31.05% |
| 10-Year Change | 32.45% |
| Growth Volatility | 25.53 |
Shinpoong Pharmaceutical Co Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shinpoong Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual net assets of Shinpoong Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩258.09 Billion | -4.69% |
| 2023-12-31 | ₩270.78 Billion | -18.13% |
| 2022-12-31 | ₩330.76 Billion | -6.71% |
| 2021-12-31 | ₩354.56 Billion | -5.28% |
| 2020-12-31 | ₩374.33 Billion | +79.00% |
| 2019-12-31 | ₩209.13 Billion | +0.79% |
| 2018-12-31 | ₩207.48 Billion | -1.25% |
| 2017-12-31 | ₩210.11 Billion | -3.11% |
| 2016-12-31 | ₩216.85 Billion | +11.28% |
| 2015-12-31 | ₩194.86 Billion | +1.75% |
| 2014-12-31 | ₩191.51 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shinpoong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 76.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩38.94 Billion | 15.16% |
| Other Components | ₩217.88 Billion | 84.84% |
| Total Equity | ₩256.82 Billion | 100.00% |
Shinpoong Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Hui Chuang Da Technology Co.Ltd
SHE:300909
|
$383.47 Million |
|
THARISA NON LIST. DL-001
F:7YZ
|
$383.53 Million |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
$383.60 Million |
|
Haesung DS Co Ltd
KO:195870
|
$383.72 Million |
|
Guangdong Jingyi Metal Co Ltd
SHE:002295
|
$383.33 Million |
|
Taier Heavy Industry Co Ltd
SHE:002347
|
$383.33 Million |
|
Cars.com Inc
NYSE:CARS
|
$383.10 Million |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
$382.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shinpoong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 269,585,828,030 to 256,820,523,460, a change of -12,765,304,570 (-4.7%).
- Net loss of 15,387,261,000 reduced equity.
- Other factors increased equity by 2,621,956,430.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-15.39 Billion | -5.99% |
| Other Changes | ₩2.62 Billion | +1.02% |
| Total Change | ₩- | -4.74% |
Book Value vs Market Value Analysis
This analysis compares Shinpoong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.16x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.76x to 3.16x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩4372.79 | ₩16450.00 | x |
| 2018-12-31 | ₩4303.11 | ₩16450.00 | x |
| 2019-12-31 | ₩4338.83 | ₩16450.00 | x |
| 2020-12-31 | ₩7577.91 | ₩16450.00 | x |
| 2021-12-31 | ₩7174.44 | ₩16450.00 | x |
| 2022-12-31 | ₩6689.68 | ₩16450.00 | x |
| 2023-12-31 | ₩5471.49 | ₩16450.00 | x |
| 2024-12-31 | ₩5212.40 | ₩16450.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shinpoong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.96%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.33x
- Recent ROE (-5.99%) is below the historical average (-3.79%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 1.76% | 1.52% | 0.54x | 2.15x | ₩-15.66 Billion |
| 2015 | 0.76% | 0.75% | 0.48x | 2.12x | ₩-17.87 Billion |
| 2016 | -8.59% | -9.58% | 0.47x | 1.92x | ₩-40.25 Billion |
| 2017 | 0.43% | 0.49% | 0.48x | 1.84x | ₩-20.08 Billion |
| 2018 | 1.36% | 1.50% | 0.49x | 1.85x | ₩-17.84 Billion |
| 2019 | 2.56% | 2.81% | 0.50x | 1.83x | ₩-15.49 Billion |
| 2020 | 1.34% | 2.53% | 0.41x | 1.30x | ₩-32.33 Billion |
| 2021 | -3.28% | -6.12% | 0.48x | 1.11x | ₩-46.93 Billion |
| 2022 | -10.73% | -16.90% | 0.58x | 1.10x | ₩-68.34 Billion |
| 2023 | -21.26% | -28.63% | 0.57x | 1.30x | ₩-84.28 Billion |
| 2024 | -5.99% | -6.96% | 0.65x | 1.33x | ₩-41.07 Billion |
Industry Comparison
This section compares Shinpoong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $472,965,132,317
- Average return on equity (ROE) among peers: 3.29%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shinpoong Pharmaceutical Co Ltd (019175) | ₩264.20 Billion | 1.76% | 0.29x | $383.38 Million |
| Dongwha Pharm.Co.Ltd (000020) | $300.87 Billion | 3.12% | 0.25x | $76.07 Million |
| Yuhan Corp Preferred (000105) | $2.15 Trillion | 3.29% | 0.37x | $3.71 Billion |
| Yuyu Pharma (000220) | $120.36 Billion | -5.97% | 0.65x | $29.69 Million |
| Ildong Holdings Co Ltd (000230) | $310.17 Billion | 8.80% | 0.65x | $48.77 Million |
| Samil Pharm (000520) | $66.60 Billion | 0.00% | 0.82x | $103.58 Million |
| Donga Socio Holdings (000640) | $1.03 Trillion | 5.64% | 0.91x | $204.37 Million |
| Jw Pharmac (001060) | $265.44 Billion | 13.94% | 1.43x | $278.79 Million |
| JW Pharmaceutical Corp (001065) | $276.31 Billion | -3.96% | 1.36x | $246.19 Million |
| Samsung Pharm (001360) | $46.24 Billion | -2.15% | 1.82x | $64.85 Million |
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | $165.68 Billion | 10.17% | 0.83x | $27.46 Million |